Pseudomonas eradication in cystic fibrosis: who will join the ELITE?
Smyth
Alan R
AR
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003550:Cystic Fibrosis / Q000150:complications*; D006801:Humans; D009894:Opportunistic Infections / Q000150:complications / Q000188:drug therapy*; D011552:Pseudomonas Infections / Q000150:complications / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa
D000900:Anti-Bacterial Agents